Suppr超能文献

长期氯氮平治疗精神分裂症伴无症状左心室功能障碍:一项多中心横断面队列研究。

Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study.

机构信息

Department of Cardiology , Concord Hospital, The University of Sydney , Sydney, New South Wales , Australia ; ANZAC Medical Research Institute , Sydney, New South Wales , Australia.

Department of Cardiology , Concord Hospital, The University of Sydney , Sydney, New South Wales , Australia ; Department of Cardiology , Canterbury Hospital, The University of Sydney , Sydney, New South Wales , Australia.

出版信息

Open Heart. 2014 Feb 26;1(1):e000030. doi: 10.1136/openhrt-2013-000030. eCollection 2014.

Abstract

OBJECTIVES

Patients with schizophrenia treated with clozapine are at risk of acute myocarditis and dilated cardiomyopathy. However, there are no data on the prevalence of subclinical cardiomyopathy or its associations.

METHODS

100 consecutive patients with schizophrenia treated with clozapine for >1 year and without a history of cardiac pathology (group 1), 21 controls with a history of schizophrenia treated with non-clozapine antipsychotics for >1 year (group 2) and 20 controls without schizophrenia (group 3) were studied. Comprehensive evaluation by clinical examination, ECG, transthoracic echocardiography including left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) and biochemical profiles were performed.

RESULTS

Patients with schizophrenia were of similar age, but had higher body mass index (BMI), rates of smoking and hyperlipidaemia than controls. Patients with schizophrenia had received clozapine or non-clozapine antipsychotics for a mean duration of 6.8±5.3 and 9.7±6.1 years, respectively. Patients taking clozapine demonstrated globally impaired LVEF (58.3%: group 1 vs 62.2%: group 2 vs 64.8%: group 3, p<0.001) and GLS (-16.7%: group 1 vs -18.6%: group 2 vs -20.2%: group 3, p<0.001). Moreover, LVEF was <50% in 9/100 (9%) patients receiving clozapine and in non-clozapine schizophrenia patients or healthy controls, but this was not statistically significantly different (analysis of covariance, p=0.19). Univariate analysis in patients taking clozapine found that impaired LV was not predicted by high-sensitivity troponin T, but was associated with features of the metabolic syndrome (including increased triglycerides, low high-density lipoprotein cholesterol (HDL-C), high-sensitivity C reactive protein and BMI), elevated neutrophil count, elevated heart rate, smoking and N-terminal probrain natriuretic peptide. In patients taking clozapine, multivariable analysis identified elevated neutrophil count and low HDL-C as the only independent predictors of impaired GLS.

CONCLUSIONS

Asymptomatic mild LV impairment is common in patients with schizophrenia receiving long-term clozapine treatment and is associated with neutrophilia and low HDL-C.

摘要

目的

接受氯氮平治疗的精神分裂症患者有发生急性心肌炎和扩张型心肌病的风险。然而,目前尚无亚临床心肌病的患病率或其相关性的数据。

方法

研究了 100 例连续接受氯氮平治疗>1 年且无心脏病史的精神分裂症患者(第 1 组)、21 例连续接受非氯氮平抗精神病药物治疗>1 年且有精神分裂症病史的对照组(第 2 组)和 20 例无精神分裂症的对照组(第 3 组)。通过临床检查、心电图、包括左心室射血分数(LVEF)和整体纵向应变(GLS)在内的经胸超声心动图以及生化谱进行综合评估。

结果

精神分裂症患者的年龄相似,但体重指数(BMI)、吸烟率和血脂异常率高于对照组。精神分裂症患者分别接受氯氮平或非氯氮平抗精神病药物治疗的平均时间为 6.8±5.3 年和 9.7±6.1 年。服用氯氮平的患者表现出整体受损的 LVEF(58.3%:第 1 组 vs. 62.2%:第 2 组 vs. 64.8%:第 3 组,p<0.001)和 GLS(-16.7%:第 1 组 vs. -18.6%:第 2 组 vs. -20.2%:第 3 组,p<0.001)。此外,9/100(9%)服用氯氮平的患者和非氯氮平精神分裂症患者或健康对照组的 LVEF<50%,但差异无统计学意义(协方差分析,p=0.19)。在服用氯氮平的患者中进行的单因素分析发现,受损的 LV 不受高敏肌钙蛋白 T 的预测,但与代谢综合征的特征相关(包括甘油三酯升高、高密度脂蛋白胆固醇(HDL-C)降低、高敏 C 反应蛋白和 BMI 升高)、中性粒细胞计数升高、心率升高、吸烟和 N 端脑利钠肽前体。在服用氯氮平的患者中,多变量分析确定中性粒细胞计数升高和低 HDL-C 是 GLS 受损的唯一独立预测因子。

结论

长期接受氯氮平治疗的精神分裂症患者中,无症状的轻度 LV 损伤较为常见,与中性粒细胞增多和低 HDL-C 相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2e9/4195917/6579196149d7/openhrt2013000030f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验